Latest Lupus erythematosus Stories
Two oral presentations at EULAR will review the impact of blisibimod on renal biomarkers and improved outcomes in systemic lupus erythematosus (SLE) patients HAYWARD, Calif., May 7, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, today announced that additional data from its Phase 2b PEARL-SC study will be presented in two lecture sessions at the...
HAYWARD, Calif., May 3, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, will release its first quarter 2013 financial report after market close on Monday, May 13(th). Anthera will host a Corporate Update conference call on May 20(th), 2013. Conference Call Access:Date: Monday, May 20(th), 2013Time: 5:00 pm Eastern Time Domestic Dial-in:...
Prominent New York Philanthropists Raise Over a Quarter of a Million Dollars at S.L.E. Lupus Foundation's 5th Annual NY Bag Ladies Luncheon NEW YORK, April 11, 2013 /PRNewswire/ -- More than 300 leaders in New York's fashion, philanthropic and lupus communities raised nearly $300,000 for the fight against lupus at S.L.E. Lupus Foundation's fifth annual New York Bag Ladies Luncheon. The support of the fashion industry with donations of over 150 handbags from 50 top designers seems...
HAYWARD, Calif., March 27, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced it has initiated the CHABLIS-SC1 Phase 3 study of blisibimod, a novel inhibitor of B-Cell Activating Factor (BAFF) for the treatment of systemic lupus erythematosus (lupus). Lupus is a chronic autoimmune disease, which often leads to severe skin rash,...
HAYWARD, Calif., March 22, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced its abstract entitled "Blisibimod, an Emerging Subcutaneous Biologic Therapy for Patients with Active, Moderate-to-Severe Systemic Lupus Erythematosus," has been selected as an oral presentation and will be presented at the 10th International Congress...
Partners to Develop Novel Nuclease Proteins for Lupus OSAKA, Japan and SEATTLE, Feb. 27, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and Resolve Therapeutics, LLC ("Resolve") today jointly announced that they have entered into a partnership to develop compounds for the treatment of lupus (also known as Systemic Lupus Erythematosus, or SLE) and other autoimmune diseases. The lead compound, RSLV-132, a novel nuclease(*1) Fc fusion protein(*2), will begin...
HAYWARD, Calif., Nov. 13, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced additional data from its Phase 2b PEARL-SC study presented in a late breaking poster at the 2012 Annual Scientific Meeting of the American College of Rheumatology and the Association of Rheumatology Health Professionals (ACR/ARHP). The poster...
NATICK, Mass., Nov. 12, 2012 /PRNewswire/ -- Karyopharm Therapeutics Inc., leading the new field of nuclear transport modulators, announces an oral presentation on the use of its SINE CRM1 antagonists for the treatment of systemic lupus erythematosus. Jennifer Anolik, MD, PhD, Associate Professor of Medicine, Department of Medicine at the University of Rochester (New York), is presenting "Novel nuclear export inhibitors deplete autoreactive plasma cells and protect mice with lupus...
HAYWARD, Calif., Nov. 1, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced that an abstract of the results from the Phase 2b PEARL-SC clinical study examining the treatment effect of blisibimod in systemic lupus erythematosus patients has been accepted as a late-breaking poster presentation at the 2012 Annual Scientific Meeting...
Grants Given to Researchers Conducting Studies that Advance Science and Medicine of Lupus WASHINGTON, Oct. 26, 2012 /PRNewswire-USNewswire/ -- A mobile application that could help young people manage their lupus is among five groundbreaking research projects that will receive grants from the Lupus Foundation of America. Researchers working in the areas of central or peripheral nervous system disorders in lupus, lupus that impacts the skin, adult stem cell research, and lupus kidney...
